Search alternatives:
teer decrease » greater decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
n decrease » nn decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
461
-
462
-
463
-
464
-
465
-
466
-
467
-
468
-
469
-
470
-
471
-
472
FUD transiently decreased IOP in mice injected with Ad5-TGFβ2 viral vector.
Published 2020“…(B) IOPs were monitored for 5 more days (until Day 22) in a subset of mice from A. …”
-
473
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
-
474
Annual number of outpatient visits in all eyes.
Published 2025“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
475
Annual treatment frequencies in all eyes.
Published 2025“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”
-
476
Annual number of outpatient visits in recurrence and non-recurrence groups.
Published 2025“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
477
Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
478
Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
479
Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
480
Image 2_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”